Chemed Corp (CHE) News
Filter CHE News Items
CHE News Results
|Loading, please wait...|
CHE News Highlights
- CHE's 30 day story count now stands at 3.
- Over the past 26 days, the trend for CHE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CHE News From Around the Web
Below are the latest news stories about Chemed Corp that investors may wish to consider to help them evaluate CHE as an investment opportunity.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors are optimistic about Chemed (CHE) on strong segmental growth and raised Roto-Rooter and earnings guidance for 2021.
CINCINNATI, August 06, 2021--Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 36-cents per share on the Company’s capital stock, payable on September 2, 2021, to shareholders of record as of August 16, 2021. This is a 2-cent, or 5.9%, increase over the 34-cent dividend paid in June 2021. The previous dividend increase was in August 2020, when the Board raised the quarterly dividend from 32-cents to 34-cents per share. This repres
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.